Decrease in serum valproic acid levels during treatment with ertapenem

American Journal of Health-System Pharmacy

Volumn 67, Issue 15, 2010, Pages 1260-1264

  Liao, Fen Fen ^a   Huang, Yaw Bin ^a   Chen, Chi Yu ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antibiotics; Anticonvulsants; Bacterial infections; Blood levels; Drug interactions; Epilepsy; Ertapenem; Valproate sodium; Valproic acid

Indexed keywords

AMBROXOL; AMLODIPINE; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAMAZEPINE; CEFPIROME; CEFTAZIDIME; CIMETIDINE; ERTAPENEM; LORAZEPAM; PHENYTOIN; TEICOPLANIN; VALPROIC ACID; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAM;

ADULT; AGED; ARTICLE; CASE REPORT; CELLULITIS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAND MAL SEIZURE; HUMAN; MEDICAL HISTORY; PRIORITY JOURNAL; TONIC SEIZURE; BLOOD; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SEIZURE; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CELLULITIS; DRUG ANTAGONISM; FEMALE; HUMANS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SEIZURES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; VALPROIC ACID;

EID: 78349284032     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090069     Document Type: Article

References (24)

1. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia. 1982; 23:693-720. (Pubitemid 13184215)
2. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006; 61:246-55. (Pubitemid 43382623)
3. Spriet I, Goyens J, Meersseman W et al. Interaction between valproate and meropenem: a retrospective study. Ann Pharmacother. 2007; 41:1130-6. (Pubitemid 47122549)
4. Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A et al. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother. 2005; 39:533-7. (Pubitemid 40270921)
5. Nagai K, Shimizu T, Togo A et al. Decrease in serum levels of valproic acid during treatment with a new carbapenem, panipenem/betamipron. J Antimicrob Chemother. 1997; 39:295-6. (Pubitemid 27116436)
6. Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy. 2007; 27:1202-5. (Pubitemid 47173664)
7. Ketter TA, Frye MA, Cora-Locatelli G et al. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol. 1999; 19:511-32. (Pubitemid 29283827)
8. Zaccara G. Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet. 1988; 15:367-89.
9. Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother. 2004; 53(suppl 2):ii11-21.
10. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004; 53(suppl 2):ii23-28.
11. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45. (Pubitemid 12149145)
12. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007; 41:674-80. (Pubitemid 46625492)
13. Kojima S, Nadai M, Kitaichi K et al. Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats. Antimicrob Agents Chemother. 1998; 42:3136-40. (Pubitemid 28553731)
14. Dickinson RG, Harland RC, Robert CH et al. Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect. J Pharmacol Exp. 1979; 211:583-95. (Pubitemid 10176078)
15. Dickinson RG, Taylor SM, Kaufman SN et al. Nonlinear elimination and choleretic effect of valproic acid in the monkey. J Pharmacol Exp Ther. 1980; 213:38-48. (Pubitemid 10099021)
16. Yamamura N, Imura-Miyoshi K, Naganuma H et al. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats. Drug Metab Dispos. 1999; 27:724-30. (Pubitemid 29252448)
17. Yamamura N, Imura K, Naganuma H. Panipenem, a carbapenem antibiotic, increases the level of hepatic UDP-glucuronic acid in rats. Drug Metab Dispos. 2000; 28:1484-6.
18. Nakajima Y, Mizobuchi M, Nakamura M et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos. 2004; 32:1383-91. (Pubitemid 39564558)
19. Torii M, Takiguchi Y, Saito F et al. Inhibition by carbapenem antibiotic imipenem of intestinal absorption of valproic acid in rats. J Pharm Pharmacol. 2001; 53:823-9. (Pubitemid 32529725)
20. Torii M, Takiguchi Y, Izumi M et al. Carbapenem antibiotics inhibit valproic acid transport in Caco-2 cell monolayers. Int J Pharm. 2002; 233:253-6. (Pubitemid 34230437)
21. Yokogawa K, Iwashita S, Kubota A et al. Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbit. Pharm Res. 2001; 18:1320-6. (Pubitemid 32846327)
22. Mori H, Mizutani T. In vitro activation of valproate glucuronidation by carbapenem antibiotics. J Health Sci. 2007; 53:302-10.
23. Omoda K, Murakami T, Yumoto R et al. Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human. J Pharm Sci. 2005; 94:1685-93. (Pubitemid 41360863)
24. Ogawa K, Yumoto R, Hamada N et al. Interaction of valproic acid and carbapenem antibiotics with multidrug resistance-associated proteins in rat erythrocyte membranes. Epilepsy Res. 2006; 71:76-87. (Pubitemid 44233201)